Investment Thesis
Apyx Medical exhibits a fundamentally challenged business model: flat revenue with zero growth, negative operating cash flow of -$572K, and net losses of -$2.1M despite healthy 63.5% gross margins. High debt-to-equity of 2.92x combined with negative interest coverage (-0.3x) means the company cannot service its $37.5M debt burden from operations, relying entirely on cash reserves that are being depleted at an unsustainable rate.
Strengths
- Strong gross margin of 63.5% indicates competitive product positioning or efficient manufacturing
- Significant cash position of $31.1M provides operational runway and debt service cushion
- Excellent short-term liquidity with current ratio of 5.80x and quick ratio of 4.79x
Risks
- Zero revenue growth (0% YoY) indicates stagnant market demand or competitive losses
- Negative operating cash flow of -$572K and free cash flow of -$632K show unsustainable cash burn
- Unprofitable operations (operating margin -7.3%, net margin -16.9%) despite reasonable gross margins suggest structural cost/scale issues
- Debt-to-equity of 2.92x with negative interest coverage means debt cannot be serviced from operations; vulnerable to covenant breaches
- Minimal insider activity (1 Form 4 filing in 90 days) suggests lack of insider confidence
Key Metrics to Watch
- Operating cash flow trajectory and cash runway depletion rate
- Revenue growth inflection and new product pipeline contribution
- Debt refinancing capability and interest coverage path to profitability
Financial Metrics
Revenue
12.5M
Net Income
-2.1M
EPS (Diluted)
$-0.41
Free Cash Flow
-632.0K
Total Assets
63.0M
Cash
31.1M
Profitability Ratios
Gross Margin
63.5%
Operating Margin
-7.3%
Net Margin
-16.9%
ROE
-16.4%
ROA
-3.3%
FCF Margin
-5.1%
Balance Sheet & Liquidity
Current Ratio
5.80x
Quick Ratio
4.79x
Debt/Equity
2.92x
Debt/Assets
79.2%
Interest Coverage
-0.32x
Long-term Debt
37.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T09:29:21.613059 |
Data as of: 2026-03-31 |
Powered by Claude AI